Dr Chiang on Frontline Treatment Combinations in ES-SCLC

In Partnership With:

Anne Chiang, MD, PhD, discusses treatment options for patients with extensive-stage small cell lung cancer.

Anne Chiang, MD, PhD, associate professor, medicine, Section of Medical Oncology, associate director, Yale Cancer Center, discusses treatment options for patients with extensive-stage small cell lung cancer (ES-SCLC).

Two frontline combinations of immunotherapy plus chemotherapy are available for patients with ES-SCLC: atezolizumab (Tecentriq) plus chemotherapy and durvalumab (Imfinzi) plus chemotherapy, Chiang says. Both combinations provide durable responses in this population, Chiang notes.

The phase 3 CASPIAN trial (NCT03043872) investigated the safety and efficacy of first-line durvalumab plus the chemotherapy regimen etoposide and carboplatin or cisplatin, durvalumab plus tremelimumab (Imjudo) and chemotherapy, or chemotherapy alone in patients with ES-SCLC, and served as the pivotal trial for the 2020 FDA approval of durvalumab plus chemotherapy in the frontline setting in this population. With 25.1 months of median follow-up, durvalumab plus tremelimumab and chemotherapy did not generate a significant overall survival (OS) improvement vs chemotherapy alone, with a median OS of 10.4 months vs 10.5 months, respectively. At a median follow-up of 39.4 months, the median OS was 12.9 months in patients who received durvalumab plus chemotherapy vs 10.5 months in those who received chemotherapy alone. In addition, the 3-year OS rates were 17.6% vs 5.8% in the durvalumab and chemotherapy arms, respectively.

The phase 3 IMpower133 trial (NCT02763579) evaluated the safety and efficacy of the combination of atezolizumab plus carboplatin and etoposide vs placebo plus carboplatin and etoposide in patients with previously untreated ES-SCLC. Findings from this trial supported the 2019 FDA approval of atezolizumab plus chemotherapy in this population. At a median follow-up of 22.9 months, the median OS was 12.3 months in the atezolizumab arm vs 10.3 months in the placebo arm. In addition, the 18-month OS rates were 34.0% and 21.0% in the atezolizumab and placebo arms, respectively.

Further research may extend the benefits of these combination regimens to more patients with SCLC, Chiang concludes.

Related Videos
Alexandra Sokolova, MD
Christie J. Hilton, DO
Yuan Yuan, MD, PhD
Jeffery Zonder, MD
Stephen V. Liu, MD
Jennifer M. King, MD
Lakshimi Nayak, MD
R. Kate (Katie) Kelley, MD
Edgardo S. Santos, MD, FACP
Andrew Katims, MD, MPH
Related Content